188 related articles for article (PubMed ID: 35385469)
1. Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention.
Mayer BT; deCamp AC; Huang Y; Schiffer JT; Gottardo R; Gilbert PB; Reeves DB
PLoS Comput Biol; 2022 Apr; 18(4):e1010003. PubMed ID: 35385469
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
[TBL] [Abstract][Full Text] [Related]
3. Broadly neutralizing monoclonal antibodies for HIV prevention.
Miner MD; Corey L; Montefiori D
J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25829. PubMed ID: 34806308
[TBL] [Abstract][Full Text] [Related]
4. Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth.
van Dorsten RT; Wagh K; Moore PL; Morris L
Front Immunol; 2021; 12():734110. PubMed ID: 34603312
[TBL] [Abstract][Full Text] [Related]
5. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
[TBL] [Abstract][Full Text] [Related]
6. Broadly neutralizing antibodies for the treatment and prevention of HIV infection.
Caskey M
Curr Opin HIV AIDS; 2020 Jan; 15(1):49-55. PubMed ID: 31764199
[TBL] [Abstract][Full Text] [Related]
7. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
Awan SF; Happe M; Hofstetter AR; Gama L
Curr Opin HIV AIDS; 2022 Jul; 17(4):247-257. PubMed ID: 35762380
[TBL] [Abstract][Full Text] [Related]
8. Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage.
Wagh K; Seaman MS
Curr Opin HIV AIDS; 2023 Jul; 18(4):164-170. PubMed ID: 37249911
[TBL] [Abstract][Full Text] [Related]
9. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
[TBL] [Abstract][Full Text] [Related]
10. Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic.
Spencer DA; Shapiro MB; Haigwood NL; Hessell AJ
Front Public Health; 2021; 9():690017. PubMed ID: 34123998
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies for HIV-1 prevention.
Julg B; Barouch DH
Curr Opin HIV AIDS; 2019 Jul; 14(4):318-324. PubMed ID: 31082819
[TBL] [Abstract][Full Text] [Related]
12. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
Cohen YZ; Caskey M
Curr Opin HIV AIDS; 2018 Jul; 13(4):366-373. PubMed ID: 29697469
[TBL] [Abstract][Full Text] [Related]
13. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
[TBL] [Abstract][Full Text] [Related]
14. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
Julg B; Stephenson KE; Wagh K; Tan SC; Zash R; Walsh S; Ansel J; Kanjilal D; Nkolola J; Walker-Sperling VEK; Ophel J; Yanosick K; Borducchi EN; Maxfield L; Abbink P; Peter L; Yates NL; Wesley MS; Hassell T; Gelderblom HC; deCamp A; Mayer BT; Sato A; Gerber MW; Giorgi EE; Gama L; Koup RA; Mascola JR; Monczor A; Lupo S; Rolle CP; Arduino R; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
Nat Med; 2022 Jun; 28(6):1288-1296. PubMed ID: 35551291
[TBL] [Abstract][Full Text] [Related]
15. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.
Wagh K; Bhattacharya T; Williamson C; Robles A; Bayne M; Garrity J; Rist M; Rademeyer C; Yoon H; Lapedes A; Gao H; Greene K; Louder MK; Kong R; Karim SA; Burton DR; Barouch DH; Nussenzweig MC; Mascola JR; Morris L; Montefiori DC; Korber B; Seaman MS
PLoS Pathog; 2016 Mar; 12(3):e1005520. PubMed ID: 27028935
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6.
Moshoette T; Papathanasopoulos MA; Killick MA
Virol J; 2022 Sep; 19(1):143. PubMed ID: 36071449
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
[TBL] [Abstract][Full Text] [Related]
18. Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS.
Wesley MS; Chiong KT; Seaton KE; Arocena CA; Sawant S; Hare J; Hernandez K; Rojas M; Heptinstall J; Beaumont D; Crisafi K; Nkolola J; Barouch DH; Sarzotti-Kelsoe M; Tomaras GD; Yates NL
Front Immunol; 2021; 12():709994. PubMed ID: 34504492
[TBL] [Abstract][Full Text] [Related]
19. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
Wagh K; Seaman MS; Zingg M; Fitzsimons T; Barouch DH; Burton DR; Connors M; Ho DD; Mascola JR; Nussenzweig MC; Ravetch J; Gautam R; Martin MA; Montefiori DC; Korber B
PLoS Pathog; 2018 Mar; 14(3):e1006860. PubMed ID: 29505593
[TBL] [Abstract][Full Text] [Related]
20. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage.
Sacks D; Wiehe K; Morris L; Moore PL
J Virol; 2022 May; 96(10):e0027022. PubMed ID: 35510865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
